ELSEVIER

Atherosclerosis 113 (1995) 297–299

ATHEROSCLEROSIS

Author index

Volume 113 (1995)

Allen, R.H., see Bostom, A.G. **113**, 129
Änggård, E.E., see Konneh, M.K. **113**, 29
Asplund, K., see Eliasson, M. **113**, 41
Attia, N., V. Durlach, J.-L. Paul, T. Soni, D. Betoulle, A. Girard-Globa, Modulation of low density lipoprotein subclasses by alimentary lipemia in control and normotriglyceridemic non-insulin-dependent diabetic subjects **113**, 197
Avogaro, A., P. Beltramello, R. Marin, S. Zambon, A. Bonanome, S. Biffanti, L. Confortin, E. Manzato, G. Crepaldi, A. Tiengo, Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients **113**, 117

Bailey, J.M., A.N. Makheja, R. Lee, T.H. Simon, Systemic activation of 15-lipoxygenase in heart, lung, and vascular tissues by hypercholesterolemia: relationship to lipoprotein oxidation and atherogenesis **113**, 247
Balasubramaniam, S., see Simons, L.A. **113**, 219
Barbacane, R., see Porreca, E. **113**, 11
Barradas, M.A., see Mikhailidis, D.P. **113**, 135
Beisiegel, U., see Reblin, T. **113**, 179
Beltramello, P., see Avogaro, A. **113**, 117
Betoulle, D., see Attia, N. **113**, 197
Betteridge, D.J., see Tan, K.C.B. **113**, 273
Biffanti, S., see Avogaro, A. **113**, 117
Blin, P., see Hugou, I. **113**, 189
Bonanome, A., see Avogaro, A. **113**, 117
Bostom, A.G., D. Shemin, M.R. Nadeau, V. Shih, S.P. Stabler, R.H. Allen, J. Selhub, Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation **113**, 129

Cavallero, E., see Dachet, C. **113**, 1
Chuang, C.H., see Hehrlein, C. **113**, 109
Clement, C., see Opper, C. **113**, 211
Cole, T., see Ordovas, J.M. **113**, 157
Confortin, L., see Avogaro, A. **113**, 117
Conti, P., see Porreca, E. **113**, 11
Cooper, M.B., see Tan, K.C.B. **113**, 273
Crepaldi, G., see Avogaro, A. **113**, 117
Cuccurullo, F., see Porreca, E. **113**, 11
Cummings, M.H., G.F. Watts, M. Umpleby, T.R. Hennessy, J.R. Quiney, P.H. Sönksen, Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study **113**, 79

Dachet, C., E. Cavallero, C. Martin, G. Girardot, B. Jacotot, Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients **113**, 1
Daret, D., see Hugou, I. **113**, 189
Di Febbo, C., see Porreca, E. **113**, 11
Durlach, V., see Attia, N. **113**, 197

Eliasson, M., K. Asplund, P.-E. Evrin, D. Lundblad, Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA study **113**, 41
Erl, W., C. Weber, C. Wardemann, P.C. Weber, Adhesion properties of Mono Mac 6, a monocytic cell line with characteristics of mature human monocytes **113**, 99
Evrin, P.-E., see Eliasson, M. **113**, 41

Ferns, G.A.A., see Konneh, M.K. **113**, 29
Freeman, D.J., see Tan, K.C.B. **113**, 273
Friedlander, Y., Sibling correlations of coronary heart disease risk factors in a sample of Israeli offspring with parental history of myocardial infarction **113**, 259

Gariepy, J., A. Simon, M. Massonneau, A. Linhart, J. Levenson, Wall thickening of carotid and femoral arteries in male subjects with isolated hypercholesterolemia **113**, 141
Girard-Globa, A., see Attia, N. **113**, 197
Girardot, G., see Dachet, C. **113**, 1
Griffin, B.A., see Tan, K.C.B. **113**, 273
Gyntelberg, F., see Suadicani, P. **113**, 63

Hales, C.N., see Tan, K.C.B. **113**, 273
Harada-Shiba, M., S. Tajima, A. Yamamoto, Response of 3-

hydroxy-3-methylglutaryl CoA reductase to *l*-triiodothyronine in cultured fibroblasts from FH homozygotes **113**, 91
Hedblad, B., see Ögren, M. **113**, 55
Hehrlein, C., M. Thompson, C.H. Chuang, R. Splinter, J.R. Tuntelder, L. Littmann, R.H. Svenson, Selective coagulation necrosis of canine adventitia and media induces extracellular matrix accumulation without neointima formation **113**, 109
Hein, H.O., see Suadicani, P. **113**, 63
Henne-Bruns, D., see Reblin, T. **113**, 179
Hennessy, T.R., see Cummings, M.H. **113**, 79
Henri, J., see Hugou, I. **113**, 189
Hornstra, G., see Katan, M.B. **113**, 133
Hugou, I., P. Blin, J. Henri, D. Daret, J. Larrue, 15-Lipoxygenase expression in smooth muscle cells from atherosclerotic rabbit aortas **113**, 189

Ikeda, H., see Sugiyama, Y. **113**, 71
Isacsson, S.-O., see Ögren, M. **113**, 55
Ishikawa, E., see Sugiyama, Y. **113**, 71

Jacotot, B., see Dachet, C. **113**, 1
Jagroop, I.A., see Mikhailidis, D.P. **113**, 135
Janzon, L., see Ögren, M. **113**, 55
Jungquist, G., see Ögren, M. **113**, 55

Kashiwagi, A., see Takagi, Y. **113**, 19
Katan, M.B., P.L. Zock, R.P. Mensink, G. Hornstra, Dietary effects on Lp(a) levels **113**, 133
Knudsen, P., see Lahdenperä, S. **113**, 227
Konneh, M.K., C. Rutherford, S.-R. Li, E.E. Änggård, G.A.A. Ferns, Vitamin E inhibits the intimal response to balloon catheter injury in the carotid artery of the cholesterol-fed rat **113**, 29
Krappe, J., see Opper, C. **113**, 211

Labeur, C., see Reblin, T. **113**, 179
Lahdenperä, S., T. Sane, H. Vuorinen-Markkola, P. Knudsen, M.-R. Taskinen, LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes **113**, 227
Larrue, J., see Hugou, I. **113**, 189
Lee, R., see Bailey, J.M. **113**, 247
Levenson, J., see Gariepy, J. **113**, 141
Li, S.-R., see Konneh, M.K. **113**, 29
Lindell, S.-E., see Ögren, M. **113**, 55
Ling, K.L.E., see Tan, K.C.B. **113**, 273
Linhart, A., see Gariepy, J. **113**, 141
Littmann, L., see Hehrlein, C. **113**, 109
Lopez-Miranda, J., see Ordovas, J.M. **113**, 157
Lundblad, D., see Eliasson, M. **113**, 41

Maegawa, H., see Takagi, Y. **113**, 19
Makheja, A.N., see Bailey, J.M. **113**, 247
Manzato, E., see Avogaro, A. **113**, 117
Marin, R., see Avogaro, A. **113**, 117
Martin, C., see Dachet, C. **113**, 1
Massonneau, M., see Gariepy, J. **113**, 141
Mensink, R.P., see Katan, M.B. **113**, 133
Meyer, N., see Reblin, T. **113**, 179
Meyermann, R., see Schluesener, H.J. **113**, 153
Mezdour, H., T. Yamamura, S. Nomura, A. Yamamoto, Exogenous supply of artificial lipoproteins does not decrease susceptibility to atherosclerosis in cholesterol-fed rabbits **113**, 237
Mezdour, H., T. Yamamura, S. Nomura, A. Yamamoto, Genetic but not diet-induced hypercholesterolemia causes low apolipoprotein A-IV level in rabbit sera **113**, 171
Mezzetti, A., see Porreca, E. **113**, 11
Mikhailidis, D.P., I.A. Jagroop, M.A. Barradas, A.F. Winder, Correlations between platelet aggregation, fibrinolysis, peripheral and central serotonergic measures in subhuman primates **113**, 135
Miki, N., see Sugiyama, Y. **113**, 71

Nadeau, M.R., see Bostom, A.G. **113**, 129
Nishigaki, I., Y. Sasaguri, K. Yagi, Anti-proliferative effect of 2-methoxyestradiol on cultured smooth muscle cells from rabbit aorta **113**, 167
Nomura, S., see Mezdour, H. **113**, 171, 237

Odaka, H., see Sugiyama, Y. **113**, 71
Ögren, M., B. Hedblad, S.-O. Isacsson, L. Janzon, G. Jungquist, S.-E. Lindell, P. Wollmer, Plethysmographic pulse wave amplitude and future leg arteriosclerosis **113**, 55
Opper, C., C. Clement, H. Schwarz, J. Krappe, A. Steinmetz, J. Schneider, W. Wesemann, Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol **113**, 211
Ordovas, J.M., J. Lopez-Miranda, F. Perez-Jimenez, C. Rodriguez, J.-S. Park, T. Cole, E.J. Schaefer, Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy **113**, 157

Packard, C.J., see Tan, K.C.B. **113**, 273
Parfitt, A., see Simons, L.A. **113**, 219
Park, J.-S., see Ordovas, J.M. **113**, 157
Paul, J.-L., see Attia, N. **113**, 197
Perez-Jimenez, F., see Ordovas, J.M. **113**, 157
Peters, W., see Simons, L.A. **113**, 219
Porreca, E., C. Di Febbo, M. Reale, R. Barbacane, A. Mezzetti, F. Cuccurullo, P. Conti, Modulation of rat vascular smooth muscle cell (VSMC) proliferation by cysteinyl leukotriene D_4: a role for mediation of interleukin 1 **113**, 11

Quiney, J.R., see Cummings, M.H. **113**, 79

Reale, M., see Porreca, E. **113**, 11
Reblin, T., N. Meyer, C. Labeur, D. Henne-Bruns, U. Beisiegel, Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques **113**, 179
Rodriguez, C., see Ordovas, J.M. **113**, 157

Rutherford, C., see Konneh, M.K. **113**, 29

Sane, T., see Lahdenperä, S. **113**, 227
Sasaguri, Y., see Nishigaki, I. **113**, 167
Schaefer, E.J., see Ordovas, J.M. **113**, 157
Schluesener, H.J., R. Meyermann, Immunolocalization of BMP-6, a novel TGF-β-related cytokine, in normal and atherosclerotic smooth muscle cells **113**, 153
Schneider, J., see Opper, C. **113**, 211
Schwarz, H., see Opper, C. **113**, 211
Selhub, J., see Bostom, A.G. **113**, 129
Shemin, D., see Bostom, A.G. **113**, 129
Shepherd, J., see Tan, K.C.B. **113**, 273
Shigeta, Y., see Takagi, Y. **113**, 19
Shih, V., see Bostom, A.G. **113**, 129
Simon, A., see Gariepy, J. **113**, 141
Simon, T.H., see Bailey, J.M. **113**, 247
Simons, J., see Simons, L.A. **113**, 219
Simons, L.A., S. Balasubramaniam, M. von Konigsmark, A. Parfitt, J. Simons, W. Peters, On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolaemia **113**, 219
Soni, T., see Attia, N. **113**, 197
Sönksen, P.H., see Cummings, M.H. **113**, 79
Splinter, R., see Hehrlein, C. **113**, 109
Stabler, S.P., see Bostom, A.G. **113**, 129
Steinmetz, A., see Opper, C. **113**, 211
Suadicani, P., H.O. Hein, F. Gyntelberg, Do physical and chemical working conditions explain the association of social class with ischaemic heart disease? **113**, 63
Sugiyama, Y., E. Ishikawa, H. Odaka, N. Miki, H. Tawada, H. Ikeda, TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters **113**, 71
Sullivan, J.L., Stored iron levels and myocardial infarction at a young age. Limitations of the study design **113**, 125
Svenson, R.H., see Hehrlein, C. **113**, 109

Tajima, S., see Harada-Shiba, M. **113**, 91
Takagi, Y., A. Kashiwagi, Y. Tanaka, H. Maegawa, Y. Shigeta, Insulin-specific activation of S6 kinase and its desensitization in cultured rat vascular smooth muscle cells **113**, 19
Tan, K.C.B., M.B. Cooper, K.L.E. Ling, B.A. Griffin, D.J. Freeman, C.J. Packard, J. Shepherd, C.N. Hales, D.J. Betteridge, Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance **113**, 273
Tanaka, Y., see Takagi, Y. **113**, 19
Taskinen, M.-R., see Lahdenperä, S. **113**, 227
Tawada, H., see Sugiyama, Y. **113**, 71
Thompson, M., see Hehrlein, C. **113**, 109
Tiengo, A., see Avogaro, A. **113**, 117
Tuntelder, J.R., see Hehrlein, C. **113**, 109

Umpleby, M., see Cummings, M.H. **113**, 79

von Konigsmark, M., see Simons, L.A. **113**, 219
Vuorinen-Markkola, H., see Lahdenperä, S. **113**, 227

Wardemann, C., see Erl, W. **113**, 99
Watts, G.F., see Cummings, M.H. **113**, 79
Weber, C., see Erl, W. **113**, 99
Weber, P.C., see Erl, W. **113**, 99
Wesemann, W., see Opper, C. **113**, 211
Winder, A.F., see Mikhailidis, D.P. **113**, 135
Wollmer, P., see Ögren, M. **113**, 55

Yagi, K., see Nishigaki, I. **113**, 167
Yamamoto, A., see Harada-Shiba, M. **113**, 91
Yamamoto, A., see Mezdour, H. **113**, 171, 237
Yamamura, T., see Mezdour, H. **113**, 171, 237

Zambon, S., see Avogaro, A. **113**, 117
Zock, P.L., see Katan, M.B. **113**, 133

ELSEVIER

Atherosclerosis 113 (1995) 300–301

ATHEROSCLEROSIS

Subject index

Volume 113 (1995)

Acyl-CoA:cholesterol acyltransferase inhibitor **113**, 71
Adhesion molecules **113**, 99
Ankle–brachial pressure index **113**, 55
Anti-proliferative effect **113**, 167
Aorta **113**, 189
Aortic smooth muscle cells **113**, 167
Apo B **113**, 179
Apo E **113**, 179
Apolipoprotein A-I **113**, 237
Apolipopoprotein A-IV **113**, 157, 171
Apolipoprotein B **113**, 79
Apolipoprotein E **113**, 157, 237
Arterial smooth muscle cell **113**, 153
Arterial thickening **113**, 109
Atherogenesis **113**, 11
Atherosclerosis **113**, 19, 55, 141, 153, 189, 237, 247

Balloon catheter **113**, 29
Betaine **113**, 129
Blood lipids **113**, 227
Blood pressure **113**, 259
BMP-6 **113**, 153

Cardiovascular diseases **113**, 211
Carotid artery **113**, 29
Chemical **113**, 63
Cholesterol **113**, 211
Cholesterol absorption **113**, 71
Cholesterol ester **113**, 197
Cholesterol esterification **113**, 71
Cholesterol-feeding **113**, 29
Cigarette smoking **113**, 41, 259
Coronary heart disease **113**, 259
Cysteinyl leukotrienes **113**, 11

Dogs **113**, 109
Drug therapy **113**, 157

End-stage renal disease **113**, 129
Enzyme immunoassay **113**, 171
Epidemiology **113**, 55
Extracellular matrix **113**, 109

Familial aggregation **113**, 259
Familial hypercholesterolemia **113**, 91
Family history **113**, 259
Ferritin **113**, 125
Fibrinogen **113**, 41

Garlic **113**, 219
Gemfibrozil **113**, 1, 117
Genetic polymorphism **113**, 157
Golden hamsters **113**, 71

Hepatic lipase **113**, 273
Heterozygous familial hypercholesterolaemia **113**, 79
HMG CoA reductase **113**, 91
HMG CoA reductase inhibitors **113**, 157
Human cell lines **113**, 71
Human umbilical vein endothelial cells **113**, 99
Hypercholesterolemia **113**, 141, 211, 247
Hyperhomocysteinemia **113**, 129
Hyperlipidemia **113**, 171
Hypertriglyceridemia **113**, 17, 227
Hypocholesterolemic activity **113**, 71

IGF-1 **113**, 19
IL-1 **113**, 11
IL-1 receptor antagonist **113**, 11
Insulin **113**, 19, 41, 273
Insulin action **113**, 117
Insulin resistance **113**, 227
Intralipid® **113**, 237
Iron **113**, 125
Ischaemic heart disease **113**, 63

Laser photocoagulation **113**, 109
LDL oxidation **113**, 219
LDL subfractions **113**, 1
Lipid-lowering diet **113**, 133
Lipids **113**, 135, 259
Lipoprotein oxidation **113**, 247
Lipoproteins **113**, 1, 179, 219
Liposomes **113**, 211
15-Lipoxygenase **113**, 189, 247

Low density lipoprotein subfractions **113**, 273
low density lipoproteins **113**, 135, 157
Lp(a) **113**, 133, 179

MAP kinase **113**, 19
2-Methoxyestradiol **113**, 167
Mild hypercholesterolaemia **113**, 219
MONICA **113**, 41
Myocardial infarction **113**, 125

Neointima **113**, 109
Non-insulin-dependent diabetes mellitus **113**, 117, 273

Obesity **113**, 259
Organic solvents **113**, 63

Peripheral arterial disease **113**, 55
Phospholipid **113**, 197, 211
Physical **113**, 63
Plasma cholesterol **113**, 219
Plasminogen activator inhibitor type 1 **113**, 41
Platelets **113**, 135, 211
Postprandial **113**, 197
Postprandial lipaemia **113**, 273
Pravastatin **113**, 157

Rabbit **113**, 189
Rat **113**, 29
Reactive oxygen species **113**, 29
Reconstituted HDL **113**, 237
Reconstituted TRL **113**, 237
Retinyl ester **113**, 197
Risk factors **113**, 55

S6 kinase **113**, 19
Serotonin **113**, 135
Small dense LDL **113**, 227
Smokeless tobacco **113**, 41
Smooth muscle cell **113**, 189
Smooth muscle cell migration **113**, 109
Social class **113**, 63
Soldering fumes **113**, 63
Stable isotopes **113**, 79

TGF-β **113**, 153
Tissue plasminogen activator activity **113**, 41
Trans fatty acids **113**, 133
Triglyceride **113**, 1, 197
l-Triiodothyronine **113**, 91
Tumor necrosis factor **113**, 99
Type 2 diabetes **113**, 227
Type IV hyperlipoproteinemia **113**, 1

Ultrasonography **113**, 141
Unesterified cholesterol **113**, 197

Vascular smooth muscle cell proliferation **113**, 11
Vascular smooth muscle cells **113**, 19
Very-low-density lipoprotein **113**, 79
Vessel wall elasticity **113**, 55
VLDL subfractions **113**, 1

Wall thickness **113**, 141
WHHL rabbit **113**, 171